Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can Zydus Cadila's Cut-Price Enzalutamide Shake Up Indian Market?

Nearly 90% Discount To Astellas/Pfizer’s Xtandi

Executive Summary

Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.

You may also be interested in...



Zydus Cadila Strengthens Pipeline With 35 FDA Approvals

India’s Zydus Cadila is working on strengthening its pipeline with 35 product approvals from the FDA over the course of its most recent financial year. The company also filed for 22 new ANDAs during FY2021. And ahead of recently launching the world’s first biosimilar to Roche’s Kadcyla (trastuzumab emtansine) in India, the company reported significant growth in its domestic business. 

Zydus Launches First Kadcyla Biosimilar in India At Sharp Discount

Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy

Gilead Remdesivir Production: Partnering, Licensing Concerns And Beximco’s Plans

Gilead has opened up discussions with potential licensing partners, including leading Indian firms, to rapidly scale up supplies of remdesivir, the antiviral that has received FDA emergency use authorization to tackle COVID-19. Healthcare activists say past licensing models used by the US firm are flawed and unacceptable during a global health emergency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142190

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel